XML 22 R5.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
Total
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Patel vs Galena biopharma, Inc
Patel vs Galena biopharma, Inc
Common Stock
Patel vs Galena biopharma, Inc
Additional Paid-In Capital
Secured Debt
Secured Debt
Common Stock
Secured Debt
Additional Paid-In Capital
Convertible Preferred Stock
Convertible Preferred Stock
Preferred Stock
Convertible Preferred Stock
Common Stock
Convertible Preferred Stock
Additional Paid-In Capital
Convertible Notes Payable
Convertible Notes Payable
Common Stock
Convertible Notes Payable
Additional Paid-In Capital
Beginning balance (in shares) at Dec. 31, 2016   0 1,268,489                              
Beginning balance at Dec. 31, 2016 $ (4,997,000) $ 0 $ 0 $ 25,434,000 $ (30,431,000)                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Stock issued in connection with amendments to MSK license, shares     83,594                              
Stock issued in connection with amendments to MSK license, amount 388,000     388,000                            
Issuance of common stock (in shares)     330,551                              
Issuance of common stock as result of conversion 1,294,000     1,294,000                            
Issuance of stock (in shares)     1,534,711                              
Issuance of stock, amount 6,007,000     6,007,000                            
Shares issued in connection with settlement of related party payables, shares     96,662                              
Shares issued in connection with settlement of related party payables, amount 378,000     378,000                            
Shares issued upon the acceleration of restricted stock units, shares     46,373                              
Shares issued upon cancellation of Equilibria restricted stock units, shares     58,208                              
Shares issued in connection with acquisition of Galena, shares     1,588,605                              
Shares issued in connection with acquisition of Galena 12,487,000   $ 1,000 12,486,000                            
Fair value of assumed options issued in connection with acquisition of Galena 32,000     32,000                            
Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, shares     632,326                              
Shares and common stock warrants issued upon conversion of 2015 Sely Note and accrued interest to Equilibria, value 6,739,000     6,739,000                            
Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria $ (675,000)     (675,000)                            
Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena, shares 119,672   119,672                              
Shares issued to Equilibria for incentive fee payment in connection with the acquisition of Galena $ 941,000     941,000                            
Shares issued to MSK for anti-dilution provisions, shares     7,700                              
Shares issued to MSK for anti-dilution provisions 61,000     61,000                            
Stock-based compensation expense 3,169,000     3,169,000                            
Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision 0                                  
Net loss (23,754,000)       (23,754)                          
Ending balance (in shares) at Dec. 31, 2017   0 5,766,891                              
Ending balance at Dec. 31, 2017 2,070,000 $ 0 $ 1,000 56,254,000 (54,185,000)                          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                                    
Issuance of common stock (in shares)   (2,898) 499,682                   (7,802) 3,748,184     118,644  
Issuance of common stock as result of conversion                       $ (8,654,000)     $ (8,654,000) $ 825,000   $ 825,000
Issuance of stock (in shares)   10,700 6,845,000       228,672     715,277                
Issuance of stock, amount 21,564,000   $ 1,000 21,563,000   $ 1,250,000   $ 1,250,000 $ 2,896,000   $ 2,896,000              
Issuance of Series A convertible preferred stock, net of offering costs 9,647,000     9,647,000                            
Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock offering (5,039,000)     (5,039,000)                            
Beneficial conversion feature arising from Series A convertible preferred stock (4,436,000)     (4,436,000)                            
Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock 4,436,000     4,436,000                            
Deemed dividend arising from the issuance of common stock to Series A convertible preferred stockholders under most favored nation provision 8,654,000     8,654,000                            
Impact of anti-dilution protection on liability-classified warrants (491,000)     (491,000)                            
Convertible preferred stock dividends (487,000)     (487,000)                            
Issuance of common stock in connection with warrant exchange agreements (in shares)     54,343                              
Issuance of common stock in connection with warrant exchange agreements 285,000     285,000                            
Issuance of common stock upon exercise of pre-funded warrants     4,049,783                              
Stock-based compensation 395,000     395,000                            
Net loss (27,670,000)       (27,670,000)                          
Ending balance (in shares) at Dec. 31, 2018   0 22,026,476                              
Ending balance at Dec. 31, 2018 $ 5,245,000 $ 0 $ 2,000 $ 87,098,000 $ (81,855,000)